Solid lipid nanoparticles; as a promising drug delivery method to get greater bioavailability: A review
Department of Pharmacology, Sojar College of Pharmacy, Khandvi Barshi 411038, Maharashtra, India.
Review
World Journal of Biology Pharmacy and Health Sciences, 2023, 14(02), 072–080.
Article DOI: 10.30574/wjbphs.2023.14.2.0104
Publication history:
Received on 16 January 2023; revised on 05 May 2023; accepted on 08 May 2023
Abstract:
Solid lipid nanoparticles (SLN) are the heart of nanotechnology's tremendous development, with multiple practical benefits in drug delivery and research. Because of their size-dependent properties, solid Lipid nanoparticles can be used to create innovative medicines. Drug conversion into nanoparticles provides a new drug delivery concept that could be used for drug targeting. As a result, solid lipid nanoparticles have great promise reaching the goal of targeted and site-specific drug delivery. The goals, production techniques, advantages, limits are all discussed in this review. Scanning electron microscopy and measurement of particle size and zeta potential, dynamic light scattering are examples of appropriate analytical techniques for SLN characterization. By using novel drug formulation technologies, the drug delivery system focuses on the regulation of in vivo dynamics in order to enhance the efficacy and safety of the included pharmaceuticals. Lipids used in the development of Nano particulate dosage forms, such as fatty acids, triglycerides, vegetable oils, and their derivatives. Solid lipid nanoparticles (SLNs) are a type of lipid drug delivery method that is relatively new. They were created to solve some of the limitations with traditional drug delivery systems, such as low drug encapsulation efficiency and limited bioavailability of Biopharmaceutical Classification Systems (BCS) class II and IV medications. SLNs are made up of physiologically well tolerated substances and melt-emulsified lipids that are solid at room temperature that helps to enhance drug bioavailability ultimately results in better desired therapeutic effect.
Keywords:
SLNs; BCS class II; Targeted drug delivery; Zeta potential; Ultra-sonication
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0